Nasdaq Grants SurgePays 180-Day Extension on $1 Bid Price; Equity Deficiency Resolved
SURG is trading near its 52-week low of $0.135 (4.0% above the low) on light trading volume (0.2× avg).
Summary
Nasdaq has extended SurgePays' bid-price compliance deadline to March 22, 2027 and confirmed that the company now satisfies the stockholders' equity requirement, eliminating one delisting threat while leaving the $1.00 bid price issue unresolved.
Key Events · Legal and Risk Events · SURG
-
180-Day Bid Price Extension Granted
Nasdaq has given SurgePays until March 22, 2027 to regain compliance with the $1.00 minimum bid price requirement. The company has stated that it may effect a reverse stock split to cure the deficiency.
-
Equity Deficiency Resolved
Nasdaq has confirmed that the company now complies with the minimum stockholders' equity requirement under Rule 5550(b)(1), resolving the deficiency described in Nasdaq's March 18, 2026 letter.
-
Delisting Risk Remains
If the company fails to evidence compliance with continued listing criteria in its next periodic report, Nasdaq may initiate delisting proceedings. The company could appeal to a Hearings Panel, but a hearing request would not stay trading suspension.
-
Reverse Split Likely
With the stock at $0.14 versus the $1.00 requirement, a reverse stock split is the stated contingency plan. The company's written notice of intent to cure included this option.
Analysis · SURG · Technology
On September 28, 2026, SurgePays received two letters from Nasdaq. The first provides an additional 180 days—until March 22, 2027—to regain compliance with the $1.00 minimum bid price requirement, and the company has indicated it may pursue a reverse stock split if needed. The second letter confirms that the company now meets the minimum stockholders' equity requirement under Rule 5550(b)(1), resolving a deficiency that was first identified on March 18, 2026. With the stock trading at $0.14, well below the $1.00 threshold, a reverse split appears to be the most likely route to compliance. Delisting remains a live risk if the company fails to demonstrate continued listing criteria in its next periodic report.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SURG was trading at $0.14 on NASDAQ in the Technology sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.13 to $3.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.